𝔖 Bobbio Scriptorium

✦ LIBER ✦

Beyond Cytotoxic Chemotherapy for the First-Line Treatment of HER2-Negative, Hormone-Insensitive Metastatic Breast Cancer: Current Status and Future Opportunities

✍ Scribed by Alison K. Conlin; Andrew D. Seidman

Book ID: 119934796
Publisher: CIG Media Group, LP.
Year: 2008
Tongue: English
Weight: 118 KB
Volume: 8
Category: Article
ISSN: 1526-8209
DOI: 10.3816/cbc.2008.n.024

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison Between Everolimus (Afinitor®

Comparison Between Everolimus (Afinitor®) and Chemotherapy Agents (Capecitabine, Docetaxel and Doxorubicin) for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast Cancer

✍ Vieira, J.; Chandiwana, D.; Taylor, M.; Lewis, L. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

476 PFS by patient subgroup for standard

476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1

✍ I. Bondarenko; J. Glaspy; A. Brufsky; O. Lipatov; E.A. Perez; S. Chan; X. Zou; S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB